.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Cerilliant
Harvard Business School
Argus Health
Citi
Accenture
Medtronic
Cipla
Julphar
Teva
Deloitte

Generated: September 25, 2017

DrugPatentWatch Database Preview

Temozolomide - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for temozolomide and what is the scope of temozolomide patent protection?

Temozolomide
is the generic ingredient in two branded drugs marketed by Rising Pharms Inc, Idt Australia Ltd, Mylan Pharms Inc, Accord Hlthcare, Merck Sharp Dohme, Chemi Spa, Sun Pharma Global, Zydus Pharms Usa Inc, Deva Holding As, Watson Labs Teva, Barr, Amerigen Pharms Ltd, Amneal Pharms, and Kremers Urban Pharms, and is included in fifteen NDAs. There are three patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Temozolomide has thirty-three patent family members in twenty-three countries.

There are sixteen drug master file entries for temozolomide. Fifteen suppliers are listed for this compound.

Summary for Generic Name: temozolomide

Tradenames:2
Patents:3
Applicants:14
NDAs:15
Drug Master File Entries: see list16
Suppliers / Packagers: see list15
Bulk Api Vendors: see list85
Clinical Trials: see list679
Patent Applications: see list6,422
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:temozolomide at DailyMed

Pharmacology for Ingredient: temozolomide

Drug ClassAlkylating Drug
Mechanism of ActionAlkylating Activity
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009RXYesYes► Subscribe► SubscribeY ► Subscribe
Amneal Pharms
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL203691-004May 8, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Amerigen Pharms Ltd
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL203490-004Jul 13, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Accord Hlthcare
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL201528-006Feb 27, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-001Aug 11, 1999ABRXYesNo► Subscribe► Subscribe► Subscribe
Watson Labs Teva
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL203959-003Apr 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Watson Labs Teva
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL203959-001Apr 18, 2017ABRXNoNo► Subscribe► Subscribe► Subscribe
Amneal Pharms
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL203691-005May 8, 2015ABRXNoNo► Subscribe► Subscribe► Subscribe
Idt Australia Ltd
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL206413-003Apr 12, 2016ABRXNoNo► Subscribe► Subscribe► Subscribe
Sun Pharma Global
TEMOZOLOMIDE
temozolomide
CAPSULE;ORAL201742-003Feb 12, 2014ABRXNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Orange Book Patents for Generic Ingredient: temozolomide

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-001Aug 11, 1999► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
POWDER;INTRAVENOUS022277-001Feb 27, 2009► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-005Oct 19, 2006► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-003Aug 11, 1999► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-006Oct 19, 2006► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-002Aug 11, 1999► Subscribe► Subscribe
Merck Sharp Dohme
TEMODAR
temozolomide
CAPSULE;ORAL021029-004Aug 11, 1999► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: temozolomide

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,674,790Processes of making and using pharmaceutical formulations of antineoplastic agents► Subscribe
8,076,335Processes of making pharmaceutical formulations of antineoplastic agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: temozolomide

Country Document Number Estimated Expiration
SloveniaEP1478339► Subscribe
Japan2005518434► Subscribe
Japan2008031186► Subscribe
World Intellectual Property Organization (WIPO)03072082► Subscribe
Austria397440► Subscribe
Norway335045► Subscribe
Japan4077794► Subscribe
MexicoPA04008133► Subscribe
South Korea20040085196► Subscribe
Portugal1478339► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Queensland Health
Chubb
Chinese Patent Office
Julphar
Dow
Federal Trade Commission
Daiichi Sankyo
UBS
Teva

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot